



Allergic Rhinitis and Immune System Targeting: Significance for the Development of Immunotherapy

Attia Thouraya *

Department of Lung Diseases and Clinical Allergology, University of Turku, Turku, Finland

DESCRIPTION

Allergic rhinitis, commonly known as hay fever, is a prevalent allergic disorder characterized by inflammation of the nasal mucosa in response to exposure to allergens. It affects a substantial portion of the global population, leading to bothersome symptoms such as sneezing, nasal congestion, itching, and rhinorrhea. Traditional treatments, including antihistamines and nasal corticosteroids, provide symptomatic relief but may fall short in addressing the root cause of allergic rhinitis. This discourse explores the significance of immune system targeting in the context of allergic rhinitis and the pivotal role of immunotherapy in its development [1-3].

Immunological basis

Allergic rhinitis is an immune-mediated response triggered by the inhalation of allergens such as pollen, dust mites, pet dander, or mold spores. In predisposed individuals, exposure to these allergens induces the release of immunoglobulin E (IgE), activating mast cells and leading to the release of inflammatory mediators, including histamine [4].

Chronic inflammation

Prolonged exposure to allergens results in chronic inflammation of the nasal mucosa. This inflammatory cascade involves an influx of immune cells, including eosinophils and T lymphocytes, contributing to the persistent symptoms experienced by individuals with allergic rhinitis.

Impact on quality of life

Beyond its physical manifestations, allergic rhinitis can significantly impact the quality of life. Sleep disturbances, impaired concentration, and diminished productivity are common consequences, highlighting the need for more effective and targeted treatment approaches [5,6].

Immune system targeting in allergic rhinitis

Desensitization strategies: Immunotherapy, or allergen-specific desensitization, represents a unique approach to address the immune dysregulation underlying allergic rhinitis. The goal is to modulate the immune response, inducing tolerance to specific allergens and thereby alleviating symptoms.

Subcutaneous Immunotherapy (SCIT): SCIT involves the administration of gradually increasing doses of allergens *via* subcutaneous injections. This form of immunotherapy has demonstrated efficacy in reducing both the severity of symptoms and the need for conventional medications. However, the injection-based nature of SCIT may pose challenges for some patients.

Sublingual Immunotherapy (SLIT): SLIT offers a more patient-friendly alternative to SCIT. Patients self-administer allergen extracts in the form of sublingual drops or tablets, allowing for convenient and comfortable treatment at home. SLIT has shown effectiveness in reducing allergic rhinitis symptoms and improving patients' quality of life.

Mechanisms of immune modulation: Immunotherapy induces changes in the immune system, promoting the development of regulatory T cells and shifting the balance away from the pro-inflammatory response characteristic of allergic reactions. This immune modulation is fundamental to the long-term success of immunotherapeutic interventions [7-9].

Significance of immunotherapy for allergic rhinitis

Disease modification: Unlike symptomatic treatments that provide temporary relief, immunotherapy has the potential to modify the course of allergic rhinitis. By inducing immune tolerance, immunotherapy addresses the underlying immune dysregulation, offering a more sustainable solution.

Reduced medication dependency: Successful immunotherapy can lead to a reduction in the need for pharmacological interventions such as antihistamines and nasal corticosteroids.

Correspondence to: Attia Thouraya, Department of Lung Diseases and Clinical Allergology, University of Turku, Turku, Finland, Email: t.attia@gmail.com

Received: 27-Nov-2023, Manuscript No. JAT-23-24389; **Editor assigned:** 30-Nov-2023, Pre QC No. JAT-23-24389 (PQ); **Reviewed:** 14-Dec-2023, QC No. JAT-23-24389; **Revised:** 21-Dec-2023, Manuscript No. JAT-23-24389 (R); **Published:** 30-Dec-2023, DOI: 10.35248/2155-6121.23.14.374

Citation: Thouraya A (2023) Allergic Rhinitis and Immune System Targeting: Significance for the Development of Immunotherapy. J Allergy Ther. 14:374.

Copyright: © 2023 Thouraya A. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This not only decreases the economic burden on patients but also mitigates the potential side effects associated with long-term medication use.

Prevention of progression: Untreated allergic rhinitis can progress to more severe allergic conditions, such as asthma. Immunotherapy has exhibits ability in preventing the progression of allergic rhinitis to asthma, making it a valuable intervention for individuals at risk of developing multiple allergic manifestations.

Long-term efficacy: While conventional treatments provide short-term relief, the efficacy of immunotherapy extends beyond the treatment period. Studies have demonstrated long-lasting benefits, with sustained symptom improvement even after the completion of a course of immunotherapy [10].

Future directions in allergic rhinitis immunotherapy

Personalized approaches: The future of allergic rhinitis immunotherapy lies in personalized treatment approaches. Advances in immunogenomics and biomarker identification may enable to customise immunotherapeutic regimens based on individual immune profiles, optimizing treatment outcomes.

Innovations in delivery systems: Ongoing research focuses on refining immunotherapy delivery systems to enhance patient adherence and comfort. Novel approaches, such as intranasal immunotherapy and sustained-release formulations, aim to improve the overall patient experience.

Combination therapies: Combining immunotherapy with other emerging treatment modalities, such as anti-IgE antibodies or small molecule inhibitors, holds promise for achieving synergistic effects and expanding the spectrum of patients who can benefit from immune system targeting.

CONCLUSION

Allergic rhinitis, with its significant impact on individuals' well-being, demands a comprehensive approach that addresses the underlying immune dysregulation. Immunotherapy, through its ability to modulate the immune response and induce tolerance, emerges as a transformative intervention in the landscape of allergic rhinitis treatment. The current insights into immune

system targeting underscore its significance in providing long-term relief and preventing the progression of allergic conditions. As research advances, the future provides potential for more personalized, patient-friendly, and synergistic approaches, solidifying immunotherapy's role in shaping the future of allergic rhinitis management.

REFERENCES

1. Wang DY. Management of allergic rhinitis in general practitioners. *Asia Pac Allergy*. 2012; 2(4):233-236.
2. Yilmaz O, Reisli I, Tahan FU, Orhan FA, Boz AB, Yuksel H. Influence of education on primary care physicians' knowledge on childhood allergy as a systemic disease and the atopic march. *Allergol Immunopathol* 2011; 39(2):73-78.
3. Bjerg A, Ekerljung L, Middelveld R, Dahlén SE, Forsberg B, Franklin K, et al. Increased prevalence of symptoms of rhinitis but not of asthma between 1990 and 2008 in Swedish adults: Comparisons of the ECRHS and GA2LEN surveys. *PloS one*. 2011; 6(2):e16082.
4. Almutawa FN, Al-Mutairy G, Al-Arada N, Kamel MI. Perception of primary care physicians about guidelines of bronchial asthma. *Alex J Med*. 2014; 50(1):17-24.
5. Salo PM, Arbes Jr SJ, Crockett PW, Thorne PS, Cohn RD, Zeldin DC. Exposure to multiple indoor allergens in US homes and its relationship to asthma. *J Allergy Clin Immunol*. 2008; 121(3): 678-684.
6. Alreshidi FM, Alrashidi AS, Alshammari FN, Qadi AB, Alrashidi AG, Alghaythi SM. Knowledge, attitude and practice about allergic rhinitis in Saudi Arabia, 2017. *Egypt J Hosp Med*. 2017; 69(4): 2199-2203.
7. Kwon JW, Kim TW, Kim KM, Jung JW, Cho SH, Min KU, et al. Differences in airway inflammation according to atopic status in patients with chronic rhinitis. *Asia Pac Allergy*. 2012; 2(4):248-255.
8. Silva CM, Barros L. Asthma knowledge, subjective assessment of severity and symptom perception in parents of children with asthma. *J Asthma*. 2013; 50(9):1002-1009.
9. Rastogi D, Madhok N, Kipperman S. Caregiver asthma knowledge, aptitude, and practice in high healthcare utilizing children: effect of an educational intervention. *Pediatr Allergy Immunol*. 2013; 26(3): 128-139.
10. Abdulrahman H, Hadi U, Tarraf H, Gharagozlou M, Kamel M, Soliman A, et al. Nasal allergies in the Middle Eastern population: results from the "Allergies in Middle East Survey". *Am J Rhinol Allergy*. 2012;26(6):S3-23.